ClinicalTrials.gg
CompletedNCT06302218Updated Nov 6, 2026

ESPB vs iPACK+ACB in Total Knee Arthroplasty

A Phase 4 interventional study of Ropivacaine 0.2% Injectable Solution and Ropivacaine 0.2% Injectable Solution in Knee Arthritis, Knee Arthropathy and Knee Osteoarthritis, sponsored by Poznan University of Medical Sciences. Completed at 1 site in Poland. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Poznan University of Medical Sciences · Phase 4, Interventional, and Treatment

How we know

Updated Nov 6, 2026Now CompletedStart date moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies testing ropivacaine in Osteoarthritis, Knee — 1 open to participants now, 2 under way, none of them phase 3. Ropivacaine · Osteoarthritis, Knee.

Enrollment
11th of 18
60 · median 64
Started
2024
with 3 others
Phase 4
15 of 18
none open now
Registered
16th of 18
by date
Lead sponsor
7 of 18
Poznan University of Medical Sciences

Among the 18 studies testing ropivacaine in Osteoarthritis, Knee, this one is the 11th largest by enrollment, is one of 4 that started in 2024, is one of 15 in phase 4, and was the 16th registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

1 of the 18 studies testing ropivacaine in Osteoarthritis, Knee is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About ropivacaine

Ropivacaine: first FDA approval 1996 (NAROPIN). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies testing ropivacaine in Osteoarthritis, Knee, or all of them as a file.
02

Study summary

Effect of iPACK block with Adductor Canal Block and ESPB on pain management, and NLR and PLR following knee arthroplasty

Read the detailed description

Knee arthroplasty is one of the most common orthopaedic procedures, especially in elderly patients, due to the deformation of joints. Patients may complain of severe pain due to surgical trauma and prostheses. Regional anaesthesia methods may be performed to reduce the surgery's induced stress response, opioid consumption, and opioid-related side effects.

In recent years, the influence of regional anesthesiology on reducing the inflammatory response after surgical procedures has been emphasised. However, very few studies have evaluated the effect of various methods of anaesthesia on the NLR and PLR.

This is the first study to investigate the effect of regional anaesthesia on the pain managementonse expres and stress respsed by the NLR and PLR in patients undergoing knee replacement surgery.

03

Conditions studied

  • Knee Arthritis
  • Knee Arthropathy
  • Knee Osteoarthritis
  • Knee Pain Chronic
  • Knee Disease
  • Knee Rheumatism
04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with I-III, Aged 20-90 years, Who will be scheduled for knee arthroplasty under spinal anaesthesia.

Exclusion criteria

Exclusion Criteria:

  • patients who have a history of bleeding diathesis,
  • take anticoagulant therapy,
  • have a History of chronic pain before surgery,
  • have Multiple trauma, cannot assess their pain (dementia),
  • have been operated on under general anaesthesia,
  • have an infection in the area and do not accept the procedure
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Active comparator
    iPACK + ACB

    spinal anesthesia \+ ultrasound guided iPACK (20ml 0,2% ropivacaine) with ACB (10ml 0.5% ropivacaine)

    Drug: Ropivacaine 0.2% Injectable Solution

  • Active comparator
    Erectro Spinae Plane Block

    spinal anesthesia \+ ultrasound guided ESPBk - 20ml 0,2% ropivacaine

    Drug: Ropivacaine 0.2% Injectable Solution

  • Placebo comparator
    Control group

    Only spinal anesthesia - No peripheral nerve block

    Drug: control group

Interventions

  • DrugRopivacaineStudies of RopivacaineRopivacaine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    iPACK block + Adductor Canal Block

    Also known as: iPACK + ACB

  • DrugRopivacaineStudies of RopivacaineRopivacaine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Erector Spinae Plane Block

    Also known as: ESPB

  • Drugcontrol group

    only spinal anesthesia

    Also known as: only spinal anesthesia

06

What researchers measure

Primary outcomes

  1. Opioid consumption

    Total opiate consumption after surgery

    Time frame: 48 hours after surgery

Secondary outcomes

  1. Time to first rescue opiate analgesia

    Time after surgery when the patient needs opiate for the first time

    Time frame: 48 hours after procedure

  2. Numerical Rating Scale [range 0:10]

    Postoperative pain assessment will be performed using the NRS score (0 = no pain, 10 = the most severe pain felt)

    Time frame: Time Frame: 4 hours after surgery

  3. Numerical Rating Scale [range 0:10]

    Postoperative pain assessment will be performed using the NRS score (0 = no pain, 10 = the most severe pain felt)

    Time frame: Time Frame: 8 hours after surgery

  4. Numerical Rating Scale [range 0:10]

    Postoperative pain assessment will be performed using the NRS score (0 = no pain, 10 = the most severe pain felt)

    Time frame: Time Frame: 12 hours after surgery

  5. Numerical Rating Scale [range 0:10]

    Postoperative pain assessment will be performed using the NRS score (0 = no pain, 10 = the most severe pain felt)

    Time frame: Time Frame: 16 hours after surgery

  6. Numerical Rating Scale [range 0:10]

    Postoperative pain assessment will be performed using the NRS score (0 = no pain, 10 = the most severe pain felt)

    Time frame: Time Frame: 20 hours after surgery

  7. Numerical Rating Scale [range 0:10]

    Postoperative pain assessment will be performed using the NRS score (0 = no pain, 10 = the most severe pain felt)

    Time frame: Time Frame: 24 hours after surgery

  8. Numerical Rating Scale [range 0:10]

    Postoperative pain assessment will be performed using the NRS score (0 = no pain, 10 = the most severe pain felt)

    Time frame: Time Frame: 36 hours after surgery

  9. Numerical Rating Scale [range 0:10]

    Postoperative pain assessment will be performed using the NRS score (0 = no pain, 10 = the most severe pain felt)

    Time frame: Time Frame: 48 hours after surgery

  10. Neutrophil-to-lymphocyte ratio

    Neutrophil-to-lymphocyte ratio

    Time frame: 24 hours after surgery

  11. Neutrophil-to-lymphocyte ratio

    Neutrophil-to-lymphocyte ratio

    Time frame: 48 hours after surgery

  12. Platelet-to-lymphocyte ratio

    Platelet-to-lymphocyte ratio

    Time frame: 24 hours after surgery

  13. Platelet-to-lymphocyte ratio

    Platelet-to-lymphocyte ratio

    Time frame: 48 hours after surgery

  14. Quadriceps muscle strength assessed using medical research council scale [range 0:5]

    Quadriceps muscle strength (knee extension and hip adduction) will be evaluated according to the medical research council muscle strength rating

    Time frame: Postoperative 24 hours period

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — Please provide the plan description

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: 6 month after study completion

Access criteria: from the corresponding author on the resonable request

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2024 to primary completion in Aug 2024, 5 months.

Of 88 non-industry phase 4 interventional studies under Osteoarthritis, Knee, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 32. This study's 5 months is below that.

Counting every sponsor, half of 97 studies reached it within 19 months; a quarter within 10 and three quarters within 36.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: start Apr 2024 → Mar 2024, primary completion Sep 2024 → Aug 2024 and completion Oct 2025 → Sep 2025.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 4, 2024
First posted
Mar 8, 2024
StartActual
Mar 8, 2024was Apr 2024
Primary completionActual
Aug 16, 2024was Sep 2024
CompletionActual
Sep 16, 2025was Oct 2025
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Completed
changed Nov 6, 2026
Start date
Apr 1, 2024→Mar 8, 2024 (actual)
Nov 6, 2026
Primary completion
Sep 30, 2024→Aug 16, 2024 (actual)
Nov 6, 2026
Study completion
Oct 30, 2025→Sep 16, 2025 (actual)
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Not yet recruiting→Completed
    Start date Apr 1, 2024→Mar 8, 2024 (now actual)
    Primary completion Sep 30, 2024→Aug 16, 2024 (now actual)
    Study completion Oct 30, 2025→Sep 16, 2025 (now actual)
    + 5 other changes: verification date, arm descriptions, contact details, data sharing statement and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06302218
Responsible party
Sponsor
First posted
Mar 8, 2024
Start date
Mar 8, 2024
Primary completion
Aug 16, 2024
Completion
Sep 16, 2025
Last update
Nov 6, 2026

Study contacts

Łukasz Łapaj, Ph.D.
study chair · Poznań University of Medical Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ropivacaine

Start the discussion